Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07744802
PHASE1
Evaluate the Effect of Vimseltinib on P-glycoprotein (P-gp) Inhibition in Healthy Male Participants
Sponsor: Deciphera Pharmaceuticals, LLC
View on ClinicalTrials.gov
Summary
The main purpose of this study is to determine the effect of vimseltinib on pharmacokinetics of P-glycoprotein (P-gp) substrate (dabigatran) in healthy male participants. This study will last approximately 21 days.
Official title: A Phase 1, Open-label, Fixed-sequence Study to Evaluate the Effect of Vimseltinib on P-glycoprotein (P-gp) Inhibition in Healthy Male Participants
Key Details
Gender
MALE
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2026-08
Completion Date
2027-12
Last Updated
2026-08-04
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
Vimseltinib
Administered orally
DRUG
Dabigatran
Administered orally